These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38647617)

  • 1. Spontaneous clearance of serum HCV-RNA after splenectomy in a patient with HCV-related liver cirrhosis and portal hypertension: a case report.
    Ogata T; Sakai T; Shibata S; Kanno H; Nakane H; Aoyagi T; Koikawa K; Sadakari Y; Hirokata G; Taniguchi M
    Surg Case Rep; 2024 Apr; 10(1):94. PubMed ID: 38647617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preoperative risk factors of portal venous thrombosis after splenectomy and gastric pericardial devascularization for portal hypertension].
    Han J; Yi Y; Ding H; Liu J; Zhang Y; Hu L; Zhao L; Liu T
    Zhonghua Gan Zang Bing Za Zhi; 2014 Oct; 22(10):739-43. PubMed ID: 25496862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir.
    Tarao K; Nozaki A; Komatsu H
    Case Rep Gastroenterol; 2021; 15(1):436-442. PubMed ID: 34054397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
    Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
    J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Rare Case of Gastric Variceal Hemorrhage Secondary to Infiltrative B-Cell Lymphoma.
    Lenhart A; Fernandez-Castillo J; Mullins K; Salgia R
    Case Rep Gastroenterol; 2016; 10(3):518-524. PubMed ID: 27843428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir and ledipasvir decreased nephrotic syndrome caused by IgA nephropathy with a membranoproliferative pattern of injury in hepatitis C virus-induced cirrhosis: a case report.
    Zhang X; Zhou J; Li C; Rao J; Li Y; Zhang J; Peng H
    Ann Transl Med; 2022 Apr; 10(8):494. PubMed ID: 35571427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease.
    Giannini EG; De Maria C; Crespi M; Demarzo MG; Fazio V; Grasso A; Torre F; Bodini G; Marabotto E; Furnari M
    Eur J Clin Invest; 2020 May; 50(5):e13231. PubMed ID: 32291753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir.
    Takakusagi S; Shimizu M; Yokoyama Y; Kizawa K; Marubashi K; Kosone T; Sato K; Kakizaki S; Takagi H; Uraoka T
    Clin J Gastroenterol; 2020 Dec; 13(6):1303-1309. PubMed ID: 32914297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of splenectomy in the treatment of non-cirrhotic portal hypertension: about 3 cases].
    Belhamidi MS; Hammi SE; Bouzroud M; Benmoussa M; Ali AA; Bounaim A
    Pan Afr Med J; 2017; 28():84. PubMed ID: 29255554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical treatment of schistosomal portal hypertension.
    Ferraz AA; Bacelar TS; Silveira MJ; Coelho AR; Câmara Neto RD; de Araújo Júnior JG; Ferraz EM
    Int Surg; 2001; 86(1):1-8. PubMed ID: 11890333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Direct-Acting Antiviral Agents on Gastroesophageal Varices in Patients with Hepatitis C Virus-Related Cirrhosis.
    Hisanaga H; Takedatsu H; Emori K; Inoue H; Kunitake Y; Nakane T; Fukunaga S; Ide T; Mitsuyama K; Torimura T
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study.
    Knop V; Hoppe D; Vermehren J; Troetschler S; Herrmann E; Vermehren A; Friedrich-Rust M; Sarrazin C; Trebicka J; Zeuzem S; Welker MW
    J Viral Hepat; 2021 Nov; 28(11):1604-1613. PubMed ID: 34342081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C.
    Rao H; Liu H; Wu E; Yang M; Feng B; Lin A; Fei R; Fontana RJ; Wei L; Lok AS
    JHEP Rep; 2020 Aug; 2(4):100136. PubMed ID: 32715286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
    El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
    Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-incision laparoscopic splenectomy for massive splenomegaly combining gastroesophageal devascularization using conventional instruments.
    Xu J; Zhao L; Wang Z; Zhai B; Liu C
    Surg Laparosc Endosc Percutan Tech; 2014 Oct; 24(5):e183. PubMed ID: 24942910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of laparoscopic splenectomy on portal haemodynamics in patients with liver cirrhosis and portal hypertension.
    Kawanaka H; Akahoshi T; Kinjo N; Iguchi T; Ninomiya M; Yamashita YI; Ikegami T; Yoshizumi T; Shirabe K; Maehara Y
    Br J Surg; 2014 Nov; 101(12):1585-93. PubMed ID: 25200126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
    J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study.
    Pereira GH; Peixoto HR; Giusti ML; Souza ML; Victor LB; Fernandes F; Perez RM; Villela-Nogueira CA
    Braz J Infect Dis; 2022; 26(5):102697. PubMed ID: 36037847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    Tada T; Kurosaki M; Nakamura S; Hasebe C; Kojima Y; Furuta K; Kobashi H; Kimura H; Ogawa C; Yagisawa H; Uchida Y; Joko K; Akahane T; Arai H; Marusawa H; Narita R; Ide Y; Sato T; Kusakabe A; Tsuji K; Mori N; Kondo M; Mitsuda A; Izumi N
    J Med Virol; 2021 Nov; 93(11):6247-6256. PubMed ID: 34170517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.